We are a clinical-stage biopharmaceutical company developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies to treat patients with cancer. We are advancing our lead TIL product candidate, ITIL-168, to treat advanced melanoma. We plan to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration and, […]

We are a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to […]

We are a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent product candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets. Our lead […]

Our mission is to build an IoT developer ecosystem and to enable everything to be smart.  We have pioneered a purpose-built IoT cloud platform that delivers a full suite of offerings, including Platform-as-a-Service (PaaS) and Software-as-a-Service (SaaS) to businesses and developers. IoT is changing the world. Our IoT PaaS offering enables businesses and developers to quickly and cost […]

We are a newly formed blank check company that will seek to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or assets, which we refer to throughout this prospectus as our initial business combination. To date, our efforts have been limited to organizational […]

We are a biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (“LSDs”), including rare genetic diseases and neurological disorders. We use our exclusively in-licensed proprietary platform, Site-Directed Enzyme Enhancement Therapy (“SEE-Tx”), to discover novel allosteric sites on misfolded proteins and identify proprietary small […]

We intend to focus our search on businesses that may provide significant opportunities for attractive investor returns. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although we expect to focus on a target in an industry where we believe our management team and founders’ […]

The Duckhorn Portfolio is the premier scaled producer of luxury wines in North America. We have delighted millions of consumers with authentic, high-quality, approachable wines for over four decades. Founded by our namesake Dan and Margaret Duckhorn in 1976, we began by pioneering Merlot wines in Napa Valley and now champion a curated and comprehensive […]

(Note:  IPOScoop has “No Call” on this offering. This is NOT a traditional IPO. This is a “step-up” or “uplift” IPO of ADS on the NASDAQ by a company whose ordinary shares trade on the Tel Aviv Stock Exchange Ltd. (TASE) under the symbol “MEAT.” From the prospectus: “This is our initial public offering of […]

Our focus will be predominantly within the technology industry and specifically on: (i) cloud infrastructure software; (ii) software as a service (SaaS) consumer and enterprise applications; and (iii) security software. Sreekanth Ravi has been chairman of our board of directors and our CEO since August 2020. Mr. Ravi has over 29 years of experience working in software and the broader technology […]